Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Lumos Diagnostics Holdings Ltd. ( (AU:LDX) ) just unveiled an announcement.
Lumos Diagnostics Holdings Ltd has reported a change in the interests of director Sam Lanyon, reflecting both direct and indirect holdings in the company’s fully paid ordinary shares and unquoted options. The notice also corrects a prior administrative error in the recorded number of securities held, confirming that all previous disclosures of Lanyon’s trades have been lodged in line with ASX Listing Rules.
On 23 April 2026, Lanyon acquired 176,276 Lumos shares via an on-market purchase valued at $29,966.92, increasing his direct shareholding while leaving his existing indirect holdings and option positions unchanged. The updated register underscores ongoing director alignment with shareholders and provides greater transparency around insider ownership for market participants and regulators.
More about Lumos Diagnostics Holdings Ltd.
Lumos Diagnostics Holdings Ltd is an Australia-listed medical diagnostics company focused on developing and commercializing rapid point-of-care tests. Its products and services target healthcare providers and diagnostic markets that require quick, accurate testing solutions to support clinical decision-making and improve patient outcomes.
Average Trading Volume: 4,576,727
Technical Sentiment Signal: Sell
Current Market Cap: A$138.4M
Learn more about LDX stock on TipRanks’ Stock Analysis page.